Netherlands: Supreme Court rules on role of description in claim interpretation

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Netherlands: Supreme Court rules on role of description in claim interpretation

Resolution Chemicals v AstraZeneca B.V. and Shionogi (Supreme Court of The Netherlands, The Hague, June 8 2018) deals with the extent of protection that is conferred by patent EP0521471 (EP 471), for rosuvastatin, a new cholesterol inhibitor.

Claim 1 of EP 471 does not claim the active ingredient of rosuvastatin (i.e. the rosuvastatin anion), but "the compound [rosuvastatin, described using its molecular formula] acid or a non-toxic pharmaceutically acceptable salt thereof''.

Resolution took the position that the feature "or a non-toxic pharmaceutically acceptable salt thereof" in claim 1 must be interpreted to only comprise the salts mentioned in paragraph [0007] of the patent, stating that "the term "a non-toxic pharmaceutically acceptable salt" refers to a salt in which the cation is an alkali metal ion, an alkaline earth metal ion, or an ammonium ion". Hence, claim 1 must be interpreted more strictly than the literal claim wording gives rise to, and rosuvastatin zinc is outside the scope.

AstraZeneca argued that the average skilled person, taking into account his general professional knowledge, would take paragraph [0007] to merely provide a non-exhaustive list of suitable salts, and that "a non-toxic pharmaceutically acceptable salt" should be understood to include the zinc salt.

The district court concluded that the skilled person would presume that the list of salts in paragraph [0007] was a conscious choice by the patentee and thus construe this paragraph as a limiting definition. It therefore ruled that the zinc salt was not within the scope of EP 471.

The Court of Appeal reversed this decision, and ruled that the average skilled person would have understood that the inventive idea does not reside in identifying suitable salt forms, but in providing a new cholesterol inhibitor having a better biological activity than existing compounds. Accordingly, he would not interpret the patent to "waive'' protection for salts of rosuvastatin other than those mentioned in [0007].

The Supreme Court rejected Resolution's complaint that the Court of Appeal had given more weight to the "essence of the invention'' than what is written in the description and affirmed the Court of Appeal's decision, indicating that it explained the patent claims in light of the common general knowledge of the average skilled person. In addition to this, it also addressed the contribution of rosuvastatin to the art, the role of salt forms in a pharmaceutical rosuvastatin composition, and the fact that EP 471 as a compound patent conferred absolute product protection. It further indicated that, when finding a fair balance according to the Protocol to Article 69 of the European Patent Convention, weight must be given to the skilled person's opinion on whether there are valid reasons for a limitation of the scope of protection. This decision indicates that the waiver doctrine as formulated in the Van Bentum v Kool decision of 2002 no longer has an independent significance as a separate test.

tepper.jpg

Annemiek Tepper


V.O.Carnegieplein 5, 2517 KJThe HagueThe NetherlandsTel: +31 70 416 67 11Fax: +31 70 416 67 99info@vo.euwww.vo.eu

more from across site and SHARED ros bottom lb

More from across our site

Attorneys explain why there are early signs that the US Supreme Court could rule in favour of ISP Cox in a copyright dispute
A swathe of UPC-related hires suggests firms are taking the forum seriously, as questions over the transitional stage begin
A win for Nintendo in China and King & Spalding hiring a prominent patent litigator were also among the top talking points
Rebecca Newman at Addleshaw Goddard, who live-reported on the seminal dispute, unpicks the trials and tribulations of the case and considers its impact
Attorneys predict how Lululemon’s trade dress and design patent suit against Costco could play out
Lawyers at Linklaters analyse some of the key UPC trends so far, and look ahead to life beyond the transition period
David Rodrigues, who previously worked at an IP boutique, said he may become more involved in transactional work at his new firm
Indian smartphone maker Lava must pay $2.3 million as a security deposit for past sales, as its dispute with Dolby over audio coding SEPs plays out
Powell Gilbert’s opening in Düsseldorf, complete with a new partner hire, continues this summer’s trend of UPC-related lateral movement
IP leaders at Brandsmiths and Bird & Bird, who were on opposing sides at the UK Supreme Court in Iconix v Dream Pairs, unpick the landmark case and its ramifications
Gift this article